Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check with administration, as I didn't pull any posts!
News for 'CEXI' - (CDEX Provides Business Update and Reports Second Quarter 2011 Financial Results)
TUCSON, AZ, Jun 15, 2011 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI), a
leading developer of chemical detection products, using patented technologies,
for use in healthcare and security markets, today provided a business update and
reported its financial results for the second quarter ended April 30, 2011.
"During the first half of the year we made tremendous progress strengthening our
distribution pipeline and reinforcing our financial position in the market. We
continued to focus on building market awareness for our ValiMed system by
attending the Amerinet Niche Technology and Supplier Fair. We shipped our first
Pocket ID2(TM) devices and signed additional distribution agreements with key
channel partners. Recently we attained CE Certification for the ID2 line,
gaining clearance for sales and distribution in European Union countries,"
stated Jeff Brumfield, chairman and chief executive officer of CDEX. "We believe
CDEX is well positioned to support increased demand for our ID2 product line and
the full launch of the new ValiMed(TM) G4 Medication Validation System later
this year. The G4 will be used as an end-of-line defense to increase patient
protection while providing a safety net for the ever increasing problem of
narcotics diversion in the clinical and hospital environments. We are very
pleased with our progress year to date. Our recent developments coupled with the
continued support of our shareholders should allow us to execute business plan
and growth strategy for the foreseeable future."
CDEX Dist. in the NEWS:Lifeloc Technologies Named a 2011 Colorado Company to Watch Award Winner
Lifeloc Technologies of Wheat Ridge, Colorado, named to the 2011 class of Colorado Companies to Watch, a Colorado Office of Economic Development and International Trade recognition program.
ShareThis Email PDF Print Denver, Colorado (PRWEB) June 06, 2011
Lifeloc Technologies, Inc., a Colorado based manufacturer of breath alcohol testers, is proud to announce that it has been officially named as a 2011 Colorado Companies to Watch award winner. Now in its third year, Colorado Companies to Watch attracted over 360 nominees. With nearly 100 companies selected as finalists, Lifeloc prevailed with other deserving firms to receive the distinction of being named to the Colorado Companies to Watch Class of 2011. The program is hosted by the Colorado Office of Economic Development and International Trade in partnership with the Edward Lowe Foundation.
Colorado Companies to Watch recognizes second-stage companies that are developing valuable products and services, creating quality jobs, enriching communities, and creating new industries throughout the state. Second-stage companies fuel the economic fire of Colorado by accounting for much of the economic growth and economic independence of individuals throughout the state.
Lifeloc Technologies has been a leading developer and manufacturer of breath alcohol testers (breathalyzers) since 1983 and has expanded its areas of expertise to include illicit drug detection and screening. John Rhoades, marketing director, commented, “From our plant and office base in Wheat Ridge, we support customers in law enforcement, corrections, workplace and schools around the world. We’re gratified to be recognized in this way.”
Lifeloc’s growth exceeded 40% in 2010. Growth was fueled by new product innovation, export development and an exceptional distributor network. We’re pleased to be recognized at home by this award,” said Barry Knott, Lifeloc president, “and we’re proud to be a Colorado manufacturer and exporter making a name for itself on the international stage. We’re dedicated to making the world safer from alcohol and drug abuse.”
About Lifeloc Technologies
Lifeloc Technologies, Inc. is a trusted international provider of precise, reliable and easy to use portable breath alcohol testing instruments (breathalyzers). We offer comprehensive online and classroom training, plus a complete line of supplies and drug screening products. Our alcohol testing devices have been manufactured continuously in Colorado since 1983. Lifeloc evidential and screening devices are approved by the U.S. DOT and many state and international regulatory agencies. More information about Lifeloc is available at
NEWS FOR CDEX ID2 Product Line Gains CE Certifications, Begins Distribution in European Union Countries
TUCSON, AZ, Jun 08, 2011 (MARKETWIRE via COMTEX) -- CDEX Inc. /quotes/zigman/334126 CEXI +2.56% , a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today its ID2(TM) Product line has successfully passed independent testing to verify conformance to the protection requirements of the European Economic Area (EEA) gaining full CE certification. The CE approval means that the entire European market is now open for the company to commercially distribute the ID2 Meth Scanner and Pocket ID2 Illicit Drug Scanner. The company will begin accelerating marketing efforts with its international distribution partners.
The CE Marking Label and the CE Declaration of Conformity are essential for product import and distribution into the European Union (EU) in compliance with all EU Regulations.
"We are very pleased to gain full CE certification allowing our current distribution partners to begin marketing our ID2 products in Europe. Strong demand exists for our innovative technology which is designed for use in law enforcement, correctional facilities and other applications where definitive and immediate results are crucial. Our ID2 meth scanner and ID2 Pocket scanner tests results are instantaneous, with the Pocket ID2 being completely non-destructive, and the ID2 meth scanner requiring a simple 'mining' process for sample gathering. Both products test for the presence of methamphetamine without the user having to touch the scanned surfaces, thus minimizing exposure to personnel and preserving the integrity of the sample substance for future analysis," stated Jeff Brumfield, chairman and chief executive officer of CDEX. "Now we can provide a safe and effective solution to European agencies to detect methamphetamines and soon other illicit drugs such as cocaine. We have received strong interest from our international distributors to gain CE approval for the ID2 product line and expect to begin shipping orders over the next 60 days."
CDEX Inc is in the StockGuru Spotlight for MAY 31, 2011
Authored by spotlight May 30, 2011 at 11:08 pm CT
DALLAS, TEXAS : StockGuru announces that CDEX Inc. (OTCBB: CEXI) is in the StockGuru Spotlight. CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2T product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched.
On Friday, the company put out news announcing the company has signed a new Master Distribution Agreement (MDA) with Decatur Electronics, Inc. to market and distribute its Pocket ID2 drug detection scanner. The new MDA provides non-exclusive marketing and distribution rights to Decatur in the U.S. and worldwide markets for the Pocket ID2.
Shares for CDEX Inc. were up during the late afternoon of trading on Friday and closed slightly up at closing.
To view the StockGuru Spotlight on CDEX Inc. (OTCBB: CEXI), please visit: http://www.stockguru.com/category/latest-spotlights/
To get free alerts on this and other similar stocks, please register here:
http://www.stockguru.com/?page_id=250
What is the StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers' attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at publisher@stockguru.com. If our reader is a key person for a publicly traded company
News for 'CEXI' - (CDEX Debenture Holders Support Company, Convert Debt to Equity)
TUCSON, AZ, Jun 02, 2011 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI), a
leading developer of chemical detection products, using patented technologies,
for use in healthcare and security markets, announced today that its debenture
holders have converted approximately $1.9 million of notes for 22.2 million
shares of common stock in the company to support future growth opportunities and
market initiatives.
"We are very appreciative of the decision by our debenture holders to convert
their debt to common equity in CDEX. We believe the conversion reflects the
confidence they have in the future prospects of the company. This transaction
significantly strengthens our balance sheet and alleviates pressure on future
cash flow," said Jeff Brumfield, chairman and chief executive officer of CDEX.
"Our team is determined to bring to market new technologies that will greatly
benefit the healthcare and securities markets. We are confident this transaction
will position us for easier access to capital to support our future expansion.
We remain focused on expanding market presence, improving financial metrics and
increasing overall shareholder value as we implement our growth strategy."
About CDEX CDEX develops, manufactures and globally distributes products to the
healthcare and security markets. The ValiMed product line provides life-saving
validation of high-risk medications and returned narcotics. The ID2(TM) product
line detects trace amounts of illegal drugs, such as methamphetamine. CDEX
expects to advance its patented technologies to serve additional markets in the
future where its proprietary products can be launched. To learn more about CDEX
please visit: www.cdex-inc.com.
Penn, I get attacked by my public post to you. You must know somebody with my email address. I have always been impartial. Why don't you just read the rules of the board. I don't pay to post as some non-shareholders do???? Thanks....
Pennstreet, all I can say is that I am not the only one removing posts. Posters that don't agree with you will file a TOS violation. Nothing I can do about it, sorry. I want and need Cdex to be a success like all of the other longtime shareholders. Good luck.
Take care....
NEWS FOR CDEX Signs New Master Distribution Agreement With Decatur Electronics for Pocket ID2 Scanner
TUCSON, AZ, May 27, 2011 (MARKETWIRE via COMTEX) -- CDEX Inc. /quotes/comstock/11k!cexi CEXI -2.50% ( www.cdex-inc.com ), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today the company has signed a new Master Distribution Agreement (MDA) with Decatur Electronics, Inc. to market and distribute its Pocket ID2 drug detection scanner. The new MDA provides non-exclusive marketing and distribution rights to Decatur in the U.S. and worldwide markets for the Pocket ID2.
Decatur has been a distribution partner with CDEX for over two years. Decatur will market the Pocket ID2 to law enforcement agencies at federal, state and local levels, correction facilities, the Department of Defense and Homeland Security agencies in the U.S. and similar agencies internationally.
"We are very excited to sign a new distribution agreement with Decatur, they have been a great partner to date and we look forward to continued success. Our new agreement provides Decatur with distribution rights worldwide for our new Pocket ID2 which is the predecessor of the ID2 Meth scanner. The Decatur sales team has tested the Pocket ID2, and the initial reaction and feedback is very favorable," stated Jeff Brumfield, chief executive officer and chairman of CDEX. "The revised MDA has built in annual sales minimums for the first three years and every year thereafter, which reflects the confidence in our products widespread appeal. Decatur will feature the Pocket ID2 at industry tradeshows as well as their marketing collateral and promotional materials, which should bolster its recognition and approval in the market."
The Pocket ID2 allows law enforcement officers and other agencies to carry and conceal the device easily providing immediate access for testing. The Pocket ID2 was developed with the Company's patented technologies that detect and verify the presence of meth at the visible and prosecutable range. Test results are instantaneous and non-destructive and can be conducted without touching or disturbing the surfaces scanned, thus minimizing officer exposure and preserving the integrity of the sample substance. The innovative technology is designed for use in law enforcement, correctional facilities and other applications where definitive and immediate results are necessary. The company is currently developing the Pocket ID2 for testing of Cocaine and other substances, which will further enhance and advance its capabilities.
About Decatur Electronics
Decatur Electronics, a Soncell NA Company, has manufactured products for public safety departments for over 50 years. As the United States' oldest manufacturer of police radar, Decatur has a long history of providing police radar, police in car video systems and speed trailers to men and women who protect our communities as well as servicing those products after the sale. To learn more about Decatur Electronics please visit www.decaturelectronics.com
News for 'CEXI' - (CDEX Participates at the Amerinet Niche Technology & Supplier Diversity Fair)
TUCSON, AZ, May 24, 2011 (MARKETWIRE via COMTEX) -- CDEX (OTCBB: CEXI)
(www.cdex-inc.com), a leading developer of chemical detection products, using
patented technologies, for use in healthcare and security markets, announced
today the company was one of only 15 companies invited to participate at the
Amerinet Niche Technology & Supplier Diversity Fair held May 12, 2011 in
Orlando, Fla. CDEX demonstrated the improved capabilities of the new
ValiMed(TM)G4 Medication Validation System to the Amerinet members and staff.
The Valimed G4 system analyzes the concentration of the drug, the diluent, the
dose in sterile parenteral admixture solutions within seconds of testing. The G4
will be used as an end-of-line defense to increase patient safety which will
help the hospitals pharmacies adhere to 797 compliance requirements. The G4 is
also capable of providing a safety net for the ever increasing problem of
narcotics diversion in the clinical and hospital environments. The purpose of
the Amerinet fair was to determine the viability for select niche healthcare
technologies to be included in the portfolio of preferred products offered
through their national healthcare group purchasing organization (GPO).
"We were very excited to be invited to present our cutting edge drug validation
technology to the members of Amerinet. The initial reaction and feedback from
attendees was very favorable and we hope to have a response regarding possible
inclusion in their vendor portfolio soon," said Jeff Brumfield, chief executive
officer and chairman of CDEX. "Our distribution partner HealthTrax, introduced
the Valimed G4 system to the Amerinet group and secured the invite to the
conference, for which we are very grateful. Amerinet is a leading national
healthcare group purchasing organization, with a membership of more than 41,000
healthcare facilities and 1,000 suppliers nationwide, access approval to the
network would provide a tremendous opportunity for CDEX."
Quite a few posts are being pulled by the administration, not me. The some posters are using the TOS for anything they disagree with. Go CDEX lets prove the nay sayers wrong!
'CEXI'CDEX SHIPS FIRST ORDER of POCKET ID2 Device to Lifeloc Technologies)
TUCSON, AZ, Jan 27, 2011 (MARKETWIRE via COMTEX) -- CDEX (OTCBB: CEXI)
(www.cdexinc.com), a leading developer of chemical detection products, using
patented technologies, for use in healthcare and security markets, announced
today the initial shipment of its new Pocket ID2 Scanner to Lifeloc
Technologies. The Pocket ID2 Scanner detects the illegal drug Methamphetamine
(Meth). Studies by the National Survey on Drug Use and Health have estimated
Crystal Meth addiction is now the largest illegal drug pandemic gripping the
nation. Lifeloc Technologies is a leading supplier of breath alcohol testers for
domestic and international law enforcement, corrections, and workplace testing.
"Management is pleased to announce this shipment of our best in class illegal
substance detectors to an industry leader such as Lifeloc," said Jeff Brumfield,
CEO and Chairman of the Board of CDEX Inc. "We believe that our Pocket ID2 is an
ideal tool for combating the multibillion dollar international methamphetamine
epidemic. Lifeloc Technologies' vast market presence and sterling industry
reputation coupled with CDEX's expansive intellectual property catalog provide
countless opportunities for future growth. We are confident that this
partnership will provide CDEX Inc. access to key law enforcement agencies and
additional sales opportunities around the world. Going forward, we will remain
focused on expanding market presence, improving financial metrics and increasing
overall shareholder value."
The Pocket ID2 allows law enforcement officers and other agencies to carry and
conceal the device easily. The Pocket ID2 was developed with the Company's
patented technologies that detect and verify the presence of meth at the visible
and prosecutable range. Test results are instantaneous and non-destructive and
can be conducted without touching or disturbing the surfaces scanned, thus
minimizing officer exposure and preserving the integrity of the sample. The
innovative technology is designed for use in law enforcement, correctional
facilities and other applications where definitive and immediate results are
necessary.
A recent report by the RAND Corporation in 2005 titled 'The Economic Cost of
Methamphetamine Use in the United States' estimated the cost of meth abuse at
$23.4 billion annually in the US, imposing serious costs to the criminal justice
system. The results of a survey conducted in 2007 by the National Association of
Counties reported by law enforcement officials from 45 states showed that Meth
is still the number one drug problem agencies deal with.
About Lifeloc Technologies For more than 25 years Lifeloc Technologies, Inc. has
served the law enforcement, corrections and workplace communities as a leading
global designer and manufacturer of professional breath alcohol testers. More
than 35 countries currently utilize Lifeloc's breath alcohol testing equipment
for workplace, DOT, law enforcement, education and corrections testing. Lifeloc
products, proudly manufactured and serviced in the USA, are recognized worldwide
for their ease-of-use, accuracy and reliability. To learn more about Lifeloc and
the Pocket ID2 Scanner please visit www.lifeloc.com.
NEWS CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced the Company will exhibit its proprietary ValiMed G4 multi-component medication and narcotic detection system, at the 45th Annual Midyear ASHP Clinical Meeting and Exhibition. The ASHP conference is being held at the Anaheim Convention Center in Anaheim, California December 6-8, 2010. The ValiMed G4 system will be featured at booth 1908 at the conference.
The fourth generation of the ValiMed Validation System significantly raises the bar for patient medication safety and pharmaceutical drug loss prevention. The ValiMed G4 provides cutting edge features and benefits over existing systems available in the market. The G4 identifies the drug, the dose, the diluents, and is the first to feature multi-component compound detection. The G4 will have an enhanced software platform for improved accuracy and reliability, while able to perform non-invasive measures of compounds directly through IV bags, syringes and vials, offering lower risk of contamination with increased workflow. In addition to validating high-risk medications before leaving the clinical or pharmacy environment, the ValiMed G4 will also monitor and discourage the diversion of controlled substances by validating the returned or unused narcotics from patient treatment areas or surgery suites. Other applications for the ValiMed G4 system include counterfeit medication monitoring, regulatory compliance and training of clinical and pharmacy personnel.
The ASHP Midyear Clinical Meeting and Exhibition is the largest gathering of pharmacists in the world. With its focus on improving patient care, the conference is attended by more than 20,000 pharmacy professionals from 86 countries. For over four decades, the ASHP Midyear Clinical Meeting has provided health-system pharmacy practitioners with a venue for updating their knowledge, networking with colleagues, enhancing their skills, and learning about the latest products and technologies available in the market.
"The ASHP Midyear conference is the largest marquee venue to showcase our new ValiMed G4 System to a national and international audience of industry professionals. We believe we are the first to offer an affordable advanced measuring system, with multi-component capabilities that will enhance and improve the quality of care that pharmacies and clinical professionals provide. This is the perfect setting for CDEX to showcase the cutting edge technology of our new ValiMed G4 System," commented Jeff Brumfield, CEO and Chairman of CDEX, Inc.
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit www.cdex-inc.com
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
News for 'CEXI' - (Independent Testing of CDEX's Improved ID2 Meth Scanner for Commercial and Home Inspection Surpasses State and National Standards)
TUCSON, AZ, Dec 01, 2010 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com), a leading developer of chemical detection products, using
patented technologies, for use in healthcare and security markets, announced the
positive results of a field test study of its improved ID2 Meth Scanner used for
commercial and home property inspection. The new version of ID2 Meth Scanner has
been recalibrated for precision measuring and convenient operation. Capabilities
of the improved ID2 Meth Scanner meet or exceed state and national requirements,
including the state of California health-based risk standards of 1.5 ug/100cm2
detected.
Independent testing was conducted by AZ Meth Detection Service(TM) at six
randomly selected vacant HUD homes located in the Phoenix and Tucson, Arizona
area. Initial mining samples were performed on 20 surface areas in each property
as a base indicator to determine if meth residue was present. The improved ID2
Meth Scanner detected the presence of hazardous methamphetamine residue at
higher levels than California's reference dose (RfD) legal standard of 1.5
micrograms/100 cm2 area, and the levels measured are considered potentially
toxic at five of the six properties. AZ Meth Detection Service's ID2 assessment
results were confirmed using a laboratory spectrometer. The cost of testing for
surface meth residue with the ID2 Meth scanner is a fraction the cost of other
technologies available and the results are real-time. The chemical swab tests
currently in use are readable for only 45 to 90 seconds and this testing method
destroys the meth residue itself in the process. The ID2 swabbed tests are
readable instantly and samples may be stored for future reference for years if
necessary, and the ID2 measuring process provides very high accuracy at locating
hazardous meth residue.
Jeff Brumfield, CEO and Chairman of the Board of CDEX Inc., commented, "We
believe our Improved ID2 Meth Scanner is the most reliable and cost effective
testing device for determining toxic levels of Meth residue in the commercial
and home Inspection markets. The team at AZ Meth Detection conducted the blind
test on randomly selected HUD homes to establish a base and verify the accuracy
of testing for surface meth residue with the improved ID2 and results were very
impressive. We are launching the ID2 Meth Scanner in December 2010 and initial
requests for purchasing the product have been very encouraging. Our research and
development team continues to develop and enhance our proprietary technologies
to serve the needs of our target markets in security and healthcare, while
providing future growth opportunities in other markets where our detection
applications will be deployed."
News for 'CEXI' - (CDEX Inc. Appoints Donald W. Strickland as Its New CEO)
TUCSON, AZ, Apr 19, 2010 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announces that its Board of Directors has appointed Donald W.
Strickland as its new CEO. Mr. Strickland, a Director of the Company, has served
in senior management positions for over 30 years and has successfully developed
businesses for both large public companies and technology startups. He has held
executive positions at Eastman Kodak Company and Apple Computer, including
heading product development, manufacturing, and sales organizations. In 1996 he
became CEO of PictureWorks Technology, a technology startup, which he sold for
$200M in 2000 to IPIX Corporation, a public company traded on the NASDAQ
exchange. Thereafter, he served as President and CEO of IPIX through 2004,
during which time he led the company through a major restructuring, focusing on
the security markets and taking the company to profitability. Mr. Strickland
holds a Bachelor's Degree in Physics from Virginia Tech, a Master's Degree in
Physics from the University of Notre Dame, a Master's Degree in Optics from the
University of Rochester, a Master's Degree in Management from Stanford
University and a Law Degree from George Washington University. He replaces
Malcolm Philips, the founding CEO and Chairman of the Board.
"Mr. Strickland is a seasoned senior executive who has demonstrated his
capability to lead both private and public companies in commercializing products
and maximizing value for shareholders," said Malcolm Philips. I can think of no
better or more qualified person to take the reins of the Company and we are very
pleased with this appointment."
"I am pleased to assume the position of CEO and look forward to a year of strong
growth and increased opportunities for the Company," said Don Strickland.
"Demand for ValiMed(TM) MVS has picked up this year and we recently announced
substantial progress made on our financial restructuring plan. These are two
important leading indicators for the success of the Company."
News for 'CEXI' - (CDEX Inc Financial Restructuring Plan Achieving Results Financial Restructuring Plan Is Providing CDEX Stability for Continued Growth in 2010)
TUCSON, AZ, Apr 16, 2010 (MARKETWIRE via COMTEX) -- On February 19, 2010 CDEX
announced it had entered into a Financial Restructuring Plan that immediately
restructured certain existing debt into two year notes, with a provision for
extending these notes to other creditors. Today, CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announces that the response of CDEX creditors to the Plan has
been strong with over 90% of the outstanding notes and over 50% of the accounts
payable being converted to long term two year notes or written off. This
restructuring of the Company's financial debt coupled with the $450,000 in
financing raised in phase one and the increase in Company revenue from its
ValiMed(TM) MVS product line (see April 14, 2010 Press Release related to new
orders) is moving the Company toward financial stability. ValiMed MVS is used to
validate the compounding of high-risk liquid medications in a pharmacy setting
and also as a verification and trending program to identify and reduce the
diversion of return narcotics in hospitals and other healthcare facilities.
"Our creditors have continued to work with us to achieve a stable financial
platform for the Company," said Stephen McCommon, CDEX's CFO. "As we continue to
seek investment funding, the financial picture is beginning to clear,
particularly with the upturn in ValiMed MVS orders across the country. With
these increased orders, 2010 is continuing to look like a return to record
revenues of 2007 and 2008."
News for 'CEXI' - (Five New Hospitals Order ValiMed(TM) MVS by CDEX to Protect Patients)
TUCSON, AZ, Apr 14, 2010 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announces it has received five orders for ValiMed(TM)
Medication Validation Systems (MVS) from new hospital clients in states
including Illinois, Pennsylvania, Florida, and Colorado. Studies worldwide
continue to show high numbers of mistakes in the compounding of high-risk
medications resulting in substantial harm to patients and economic loss to
hospitals. ValiMed MVS is used to validate the compounding of high-risk liquid
medications in a pharmacy setting and also as a verification and trending
program to identify and reduce the diversion of return narcotics in hospitals
and other healthcare facilities.
"The new orders for ValiMed(TM) MVS Units demonstrate the traction we are
gaining with the new marketing direction that I introduced at CDEX last year,"
said Greg Firmbach, CDEX President. "I have expanded the sales force in the wake
of these new orders and expect the momentum to grow over this year. We are
looking at additional sales channels to take advantage of the loosening medical
budgets and the growing recognition that human errors in the compounding of high
risk medications are harming patients -- directors of pharmacy know this to be
the case and ValiMed(TM) MVS provides another arrow in their quiver of tools to
protect patients, all for about $2.70 per test."
Or was his name Col. Klink from Hogans Hero's?
News for 'CEXI' - (Medication Safety and Narcotic Diversion Prevention Equipment Showcased by CDEX at HCP)
TUCSON, AZ, Apr 12, 2010 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announces demonstration of its ValiMed(TM) Medication
Validation System (MVS) to Directors of Pharmacy at the Health Connect Partners
(HCP) Reverse Expo in San Diego, CA on April 12-14. Studies worldwide continue
to show unacceptable frequency of mistakes in the compounding of high-risk
medications resulting in substantial harm to patients and economic loss to
hospitals. In an 18-month University of Michigan Health System study, ValiMed
identified 5 major medical errors (see
http://www.ns.umich.edu/htdocs/releases/story.php?id=6255). ValiMed MVS is used
to validate the compounding of high-risk liquid medications in a pharmacy
setting and also as a verification and trending program to reduce the diversion
of return narcotics in hospitals and other healthcare facilities.
"ValiMed MVS is another arrow in the quiver of pharmacy directors who have
patient safety as one of their top priorities," said Greg Firmbach, CDEX
President. "ValiMed MVS provides a technological safety net in the compounding
of high risk medications and the 'Quality and Quantity' tools necessary to
identify and prevent narcotic diversion."
"HCP is a unique venue allowing CDEX to talk one-on-one with hospital Pharmacy
Directors about patient safety," continued Firmbach. "During the three-day
event, CDEX's three attending employees will have the potential of making over
90 quality presentations to hospital decision makers as well as networking with
the over 200 hospital directors attending. This type of show fits perfectly into
our strategic mix of marketing efforts designed to place at least one ValiMed
MVS in every major hospital."
The long current non shareholders are huffing and puffing for 10 years.
Amounts to less than power of a bit of goose down in a tornado.
What doesn't make any sense at all, is the time you non shareholders spend protesting. The length and the amount of your posts, just doesn't add up? Not to mention the amount of years you non shareholders have been protesting. Look at how much time it takes you to protest a stock that you don't own! No it doesn't make any sense, and is very boring.
It's very simple. MP out and JB in! Most of the shareholders want this, if not all of the shareholders. Besides MP's buddies who hold shares. We the Cdex shareholders have nothing to lose at this point. If there is any hope left, it is not to be wasted with Malcolm!
As to the non-shareholders, we don't care what you have posted or will post. You have said the same things over and over for years. You must enjoy reading your own posts. Very boring to say the least!
"Go to all the trouble"? Are you serious? Look at all the trouble you non-shareholders have gone thru to post for 10 years.
An email to MP from Raider. Good job Raider.
Malcolm,
Thank you for your note.
I appreciate your attempt to rationalize the lack of progress this company has seen under your leadership.
The bottom line is that you have done a less-than-stellar (I’m trying my best to be nice) of moving this company forward in your eight years as CEO. The bottom line is that thousands of investors have lost billions of dollars in this investment under your tenure. Your assertion to numerous investors, including this one, that CDEX would be operating in the red as early as 2006 simply has not come true, then, now, or anytime in between. Our annual revenues, touted by you as "record" almost each and every year, have grown insignificantly in your eight years as CEO. Our last reported annual revenues, for the year ending October 31, 2008, long before the recession that you cite as a major reason for this company's poor performance, were a little over $800,000. The vast majority of mom and pop convenience stores do over $800,000 in revenues each year in their first year of operation, yet seven years after you took over, we were still under $1 million in annual revenues.
No other publicly-traded company in the history of America would look at this eight-year performance and hire the former CEO as a consultant to do the same job. Yet, CDEX did. This is unbelievable to anyone who believes in management accountability.
Although it's easy for you to blame the downturn in the company's PPS performance on the economy, the charts show a much different story. On August 10, 2009, with you leading our company months before the financial collapse that started in October 2009, the company's stock closed at .06, with a low of less than 5 cents. On December 14, 2009, at the height of the economic downturn, the stock price closed at .05. As you can see, and as the charts attest, the downturn in our company occurred before the deep recession faced by our country. This downturn occurred on your watch.
Looking at your performance long-term provides an even more sobering assessment. On March 7, 2005, the stock price closed at $1.35. Yesterday the stock closed at .075 or only 6 percent of its value almost exactly five years ago. In other words, if someone invested $10,000 in CDEX on March 7, 2005, when you clearly were leading our company, yesterday that investor had only $600. For all but a little less than one year during that time period, you were at the helm of the ship. Instead of growing shareholder value, the value to shareholders has declined precipitously.
For you to try to avoid blame for the terrible PPS storm caused by the lawsuit is kind of like assigning blame solely to President Barack Obama for the recession that continued into 2009. The table had been set under your leadership, Malcolm, just as the table had been set under President George Bush and previous administrations for the recession faced by America in 2008-10. I was told by a person whom I trust that you, Malcolm, knew about this lawsuit long before you left and that certain actions taken by you could have avoided the legal fees and decline in the PPS caused by prolonged legal uncertainty. Unfortunately, according to my sources, your stubbornness once again cost this company. Whether or not this is true or just another "rumor" made up by your detractors, your timing was impeccable in leaving the helm before the lawsuit was filed, but returning to the wheel after it was settled.
Whether you want to admit it or or not, Malcolm, you have done a less than admirable (again I’m trying to be nice) job as CEO, and your actions and lack of leadership have cost investors billions. Perhaps you did some good things in the beginning, and I'm sure you did, but in my opinion, and in the opinion of dozens of other investors and employees who talked with you often, your stubbornness and ego prevented this company from reaching its true potential.
You just don't get it, Malcolm, and you never will. From our very first phone conversation, I sensed a sincere disdain for the average shareholder. In our most recent conversations, I sensed the very same arrogance that I felt on that very first call. You bragged how easily it would be for you to take the company private or bankrupt. Any CEO of a publicly-traded company who would brag at taking action that would harm shareholders is despicable in my book.
Most CDEX investors are good people, Malcolm, but they have lost billions of dollars, as well as their hopes and dreams for an early retirement and the opportunity to pass on a better life to their children. If shareholders felt that you had sincerely tried your best but failed, they would be disappointed, but not angry. But knowing what I know now, after talking with so many people who have had dealings with you over the years, I realize that your stubbornness and ego were routinely put above the best interests of the company and its shareholders.
That’s inexcusable. Yet, you remain in control of the company you have all but bankrupted.
Congratulations, Malcolm. You have done the one job you set out to do -- maintain control of the company!
Pennstreet, he talks like a Republican, and acts like Obama and crew. How embarassing he is to himself. Attacking people to destroy their credibilty. All I did was defend the shareholders, with one paragraph. I agree with you and many others who want JB in as CEO.
Whatsdamatter? Shareholders have no rights here? You all have been repeating yourselves for years, and I think you have no finacial intrest in seeing CDEX succeed. Pennstreet these people can't stand to be disagreed with. I hope you keep posting. I would also like JB to become CEO. It beats having MP as the puppet master anyday!
NEWS:CDEX Inc Announces Financial Restructuring Plan
http://www.earthtimes.org/articles/show/cdex-inc-announces-financial-restructuring-plan,1171612.shtml
TUCSON, AZ -- 02/19/10 -- CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces that it has closed the first phase of a financial restructuring plan which provides funds to drive expanded marketing and sales, conversion of existing debt into a two year Note and an offering to certain other creditors to also participate in the Note. The specifics of the restructuring plan are provided in the Company's SEC filings, but include an initial cash infusion of $450,000 with an opportunity for follow on investment and a restructuring of the note held by the Company's largest creditor, Gemini Master Fund, Ltd.
In addition, the Board of Directors has appointed Mr. Carmen Conicelli as its new Chairman. Mr. Conicelli, the current CFO of Edmund Optics, Inc., joined the Board in 2008 with over 30 years of industry financial experience and a strong focus in the international community.
"Mr. Conicelli has been at the heart of our financial restructuring and I am very pleased with his appointment," said Malcolm Philips, CDEX CEO and former Chairman. "His appointment, which follows our recent announcement of appointment of Greg Firmbach as the Company's new President and initiation of a CEO search, continues our strategy of focusing the company on top line revenue and strong financial performance."
"The financial restructuring will allow us to fund our short term growth plans and move to the next level," said Mr. Conicelli. "It puts the Company on more solid financial footing and is beginning to draw out some very well qualified CEO candidates. The Board looks forward to working with the new management team to move the Company forward."
News for 'CEXI' - (CDEX Appoints Gregory Firmbach as President)
TUCSON, AZ, Feb 10, 2010 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announced today that its Board of Directors has appointed
Gregory Firmbach as its new President. Firmbach, formerly CDEX Senior Vice
President, has served for over 25 years in senior positions in the healthcare
industry. He has led divisions and companies (both public and private) in all
aspects of successful development, launch and expansion of both software and
hardware products related to the healthcare industry. In his new role, he will
lead the company's strategic growth.
"Greg is a seasoned executive with outstanding credentials in the successful
development and launch of healthcare products in both public and private
companies," said Malcolm Philips, CDEX CEO. "He has designed and implemented our
sales and marketing strategies during these turbulent economic times and his
appointment gives greater focus to revenue production as our continuing top
priority."
"I am honored with this appointment and will continue to make revenue production
the top priority for CDEX," said Firmbach. "We are ideally positioned to make
2010 a banner year focused on revenue growth and product development. We
recently enhanced our revenue model to ready our company for growth including
significant changes to our customer service and marketing focus."
"The goal I am setting for the Medication Safety Division is to establish the
CDEX ValiMed(TM) Medication Validation System (MVS) as the standard for
prevention of human error in the compounding of high risk medications and the
diversion of hospital narcotics," Firmbach continued.
Firmbach said the company will also fully support the efforts of the Emily Jerry
Foundation and The Quaid Foundation to prevent human error in hospitals. The
Emily Jerry Foundation recently endorsed the life-saving capability of the CDEX
technology. The ValiMed MVS delivers a real time validation of The Right Drug at
The Right Dose for about $2.50 per test.
NEW-PR TODAY January 19, 2010 - EMILY JERRY FOUNDATION ENDORSES LIFE-SAVING TECHNOLOGY NON-PROFIT SUPPORTS THE VALIMED™ MEDICATION VALIDATION SYSTEM BY CDEX
Device is clinically proven to save lives
CLEVELAND, OHIO – January 19, 2010Nearly four years after the loss of Christopher Jerry’s two-year-old daughter, Emily, the anguish over her accidental death lingers on. Now, as the head of a non-profit foundation working to prevent medical errors, Jerry is entering the new year with a renewed sense of purpose promoting an all-new life-saving technology in honor of Emily.
Today, the Emily Jerry Foundation announced a new partnership with CDEX, Inc. to build public awareness about its pioneering chemical detection equipment designed to ensure medical facilities are delivering the right medications to patients.
Jerry, who formed the non-profit group to push for federal legislation to avoid medical errors like the one that claimed his daughter’s life, is actively promoting the life-saving capability of the CDEX ValiMed™ Medication Validation System (MVS) as an imperative device in the prevention of human pharmaceutical errors. Jerry endorsed the product as life-saving equipment that could prevent the death of other toddlers.
ValiMed™ MVS is a technological safety net that provides protection from medication errors for patients, pharmacists and hospitals. The table-top device - engineered to eliminate mistakes made while mixing compounds at a hospital - uses a technique called enhanced photoemission spectroscopy to determine if the compounds are correct.
“I plan to do everything possible in my daughter’s memory to prevent these horrible tragedies from occurring over and over again,” said Jerry, president and chief executive officer of the Mentor, Ohio-based Emily Jerry Foundation. “Technology like the CDEX ValiMed™ MVS equipment is clinically proven to save lives and can prevent the death of other children.”
Emily Jerry died in March 2006 when a pharmacy technician’s mistake led to the delivery of a fatal dose of saline solution. Her death came only three days after receiving the lethal dose during what should have been her final chemotherapy treatment. The grapefruit-sized tumor in her abdomen was gone and her parents were planning a trip to Disney World when the toxic mixture was administered.
“ValiMed™ MVS is the only technology available today that prevents harm to patients from human errors in the compounding of high-risk medications,” said Jerry. “We can immediately begin saving lives with the ValiMed™ MVS system. Let’s act now to prevent any more senseless deaths from occurring by asking all medical facilities compounding intravenous medications to install and use the ValiMed™ MVS by CDEX in their pharmacies
News for 'CEXI' - (ValiMed(TM) MVS Draws Large Crowds and High Praise at ASHP Conference ValiMed MVS Should Be Required at All Hospitals - Emily Jerry Foundation)
TUCSON, AZ, Dec 14, 2009 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) announces that it presented the lifesaving capability of its
ValiMed(TM) MVS (Medication Validation System) with new onsite data collection
options to a great number of interested hospital pharmacists and safety
specialists at the Las Vegas ASHP Conference (December 7-9, 2009). Worldwide
studies continue to show that human errors in the compounding of high-risk
medications occur frequently and result in permanent harm to patients and that
the diversion of medical narcotics is a continuing problem. ValiMed MVS is a
technological safety net that provides protection for patients, pharmacists and
hospitals.
"I saw the ValiMed MVS demonstrated at the ASHP Conference and my conclusions
are that it should be required at all hospitals -- technology like this could
have prevented the death of my daughter," said Chris Jerry, President of the
Emily Jerry Foundation (www.emilyjerryfoundation.org). "At the Conference,
Dennis Quaid talked about the frequency of human errors and the need for
technology to protect against them. From what I have seen, ValiMed is the only
technology available today that prevents harm to patients from human errors in
the compounding of high-risk medications. I believe that those hospitals which
have adopted the ValiMed MVS as part of their Medication Safety Programs have
set the standard of care and all hospitals should follow suit."
"With the new policy of zero tolerance to medication errors announced by the
Joint Commission the interest in ValiMed MVS was high -- human errors happen,"
said Greg Firmbach, CDEX Senior VP. "We had our largest number of CDEX
representatives ever at a conference and presented the ValiMed MVS capabilities
to the largest number of hospital representatives ever at the booth. It looks
like 2010 is stacking up to be an exciting year as hospital budgets are
beginning to loosen and the ValiMed MVS Pay-Per-Use Pricing gets into full
swing."
What leadership style? "Hey you are not a born again we can't do business with you"? What kind of style is that? The man has no style, except the cowardly so called good Christian, and bad businessman style. He gives all Christians a bad name. He is set for life however! That must be nice, as I wouldn't know. One thing for sure CEO's don't get much worse than Philips! What a relief it will be to have the face that sank a 1000 ships gone! Thanks for your post.
"Are you guys rooting for cdex, or are you wanting to see the company fail"?
Why can't you answer the question? You negative posters have been posting for years and years with the same repitious rap over and over at nausium. You are the ones who are boring. You attack shareholders all the time. When it's none of your business. Don't you have anything better to do than post on a penny stock board day in and day out? Good grief! Take a break already.
Although I replied to pennstreet, this post is meant for the gang that couldn't shoot straight.
EVEN MORE NEWS for 'CEXI' - (ASHP 2009 Research Award Presented to Research Team From the University of Michigan Health System Study on Compounding Accuracy of High-Risk Medications Wins ASHP Research Award)
TUCSON, AZ, Dec 03, 2009 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) extends its congratulations to Dr. Jim Stevenson and members
of his staff at the CS Mott Children's Hospital of the University of Michigan
Health System, among the best in the nation, recipients of the 2009 ASHP
Literature Award for Pharmacy Practice Research. Their study assessed the
sensitivity and specificity of the ValiMed Medication Validation System (MVS)
when used to confirm the admixture of high-risk parenteral medications. In the
paper they also reported that in the first 18 months of use they identified five
major medical errors that would have otherwise caused substantial harm to
patients (http://www.cdexinc.com/pages/Stevenson_AJHP.pdf). Thanks to the
courageous efforts of Dr. Stevenson and his staff, many Directors of Pharmacy
around the world now better understand the reality that undetected, major errors
in the compounding of high-risk medications are happening today in many
hospitals and a technological safety net (such as the ValiMed MVS) is needed to
protect patients.
CDEX will be demonstrating the lifesaving capabilities of the ValiMed MVS at the
ASHP Mid-Year Conference (Venetian Hotel & Sands Expo Center) in Las Vegas on
December 7-9, 2009. Dennis Quaid, representing the Dennis Quaid Foundation, will
provide a keynote address at the Conference. CDEX invites all those interested
in medication safety to stop by Booth # 743 and learn how ValiMed MVS is saving
lives in major hospitals today.
MORE NEWS:December 3, 2009 - ASHP 2009
RESEARCH AWARD PRESENTED TO RESEARCH TEAM FROM
THE UNIVERSITY OF MICHIGAN HEALTH SYSTEM
Study on compounding accuracy of high-risk medications wins ASHP Research
Award.
Tucson, Arizona - December 3, 2009 - CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) extends its congratulations to Dr. Jim Stevenson and
members of his staff at the CS Mott Children's Hospital of the University of
Michigan Health System, among the best in the nation, recipients of the 2009
ASHP Literature Award for Pharmacy Practice Research. Their study assessed
the sensitivity and specificity of the ValiMed Medication Validation System
(MVS) when used to confirm the admixture of high-risk parenteral
medications. In the paper they also reported that in the first 18 months of
use they identified five major medical errors that would have otherwise
caused substantial harm to patients (Read the report here.
http://www.cdexinc.com/pages/Stevenson_AJHP.pdf). Thanks to the courageous
efforts of Dr. Stevenson and his staff, many Directors of Pharmacy around
the world now better understand the reality that undetected, major errors in
the compounding of high risk medications are happening today in many
hospitals and a technological safety net (such as the ValiMed MVS) is needed
to protect patients.
CDEX will be demonstrating the lifesaving capabilities of the ValiMed MVS at
the ASHP Mid-Year Conference (Venetian Hotel & Sands Expo Center) in Las
Vegas on December 7-9, 2009. Dennis Quaid, representing the Dennis Quaid
Foundation, will provide a keynote address at the Conference. CDEX invites
all those interested in medication safety to stop by Booth # 743 and learn
how ValiMed MVS is saving lives in major hospitals today.
News for 'CEXI' - (CDEX Projects Record Placements of ValiMed(TM) MVS Units in 2010)
TUCSON, AZ, Dec 02, 2009 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) CEO and Chairman, Malcolm Philips, reviews CDEX's performance
through 2009 and sets the stage for 2010 in the "CEO Corner" of the CDEX Web
Site. Mr. Philips reflected upon CDEX's progress through the global economic
downturn of 2009, concluding that based on recent sales activity 2010 will be a
year of record placements of ValiMed(TM) MVS units, driven by improving economic
conditions and the recent introduction of the "Pay Per Use" pricing plan for
hospitals. The list of world class hospitals that have made ValiMed MVS a part
of their Medication Safety and Narcotic Return Validation Programs continues to
grow and lives are being saved. In addition, Tim Shriver, CDEX COO, provides a
management briefing update on technological advancements in the CDEX product
lines. For a complete review of the briefings, please go to the "CEO Corner" of
the Management Briefing section of the CDEX Web Site (www.cdexinc.com).
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare
and security markets. The ValiMed product line provides life-saving validation
of high-risk medications and returned narcotics. The ID2(TM) product line
detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to
advance its patented technologies to serve additional markets. To meet its
plans, CDEX must strengthen its financial position as stated periodically in its
SEC filings. For more information, contact Malcolm Philips at
mphilips@cdex-inc.com.
Non-historical statements are forward-looking, as defined in federal securities
laws, and generally can be identified by words such as "expects," "plans,"
"may," "believes," "should," "intends," and similar words. These statements pose
risks that cannot be accurately predicted. Consequently, results may differ
materially from those expressed or implied. Such risks and uncertainties
include, without limitation, the effectiveness, profitability and marketability
of products, the protection of intellectual property and proprietary
information, and other risks detailed periodically in filings with the SEC.
There is no obligation to update any forward-looking statements.
December 1, 2009 - THE LIFESAVING CAPABILITY OF VALIMEDT MVS TO BE DEMONSTRATED AT THE ASHP CONFERENCE
Tucson, Arizona - December 1, 2009 - CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) will demonstrate its ValiMedT MVS with new onsite data collection options at the ASHP Conference (Venetian Hotels & Sands Expo Center) in Las Vegas on December 7-9, 2009. Dennis Quaid, representing the Dennis Quaid Foundation, will provide a keynote address at the Conference. CDEX invites all those interested in medication safety to stop by Booth # 743 and learn how ValiMed MVS is saving lives in major hospitals today.
"The ASHP Mid-Year meeting presents an opportunity for CDEX to inform the Directors of Pharmacy from the nation's hospitals about the benefits of incorporating the ValiMed MVS into their pharmacy workflow," said Greg Firmbach, CDEX Senior VP. "ValiMedT MVS is increasing overall patient safety as a final check in the prevention of human error in the compounding of high-risk medications and as the central validation point for the disposal of narcotics as part of a narcotic diversion prevention program."
Worldwide studies continue to show that human errors in the compounding of high-risk medications occur frequently and result in permanent harm to patients throughout the world and that the diversion of medical narcotics is a continuing problem. ValiMedT MVS is a technological safety net that provides protection for patients, pharmacists and hospitals.
News for 'CEXI' - (ValiMed(TM) MVS and ID2 Meth Scanner(TM) by CDEX Awarded GSA Contract Status ABMI GSA Contract Now Includes CDEX Products for Government Sales)
TUCSON, AZ and SACRAMENTO, CA, Nov 23, 2009 (MARKETWIRE via COMTEX) -- CDEX
Inc. (OTCBB: CEXI) (www.cdexinc.com) and All Business Machines, Inc. ("ABMI")
(www.abmicorp.com) announce that the ValiMed(TM) MVS (Medication Validation
System) and ID2 Meth Scanner(TM) product lines by CDEX have been placed on the
ABMI GSA Contract Schedule. ValiMed MVS puts a technological safety net between
the patient and errors made in the compounding of high risk medications and
guards against narcotic diversion. Both are now available to the Government
markets through the ABMI GSA Schedule.
"Medical studies demonstrate that human errors in compounding of high-risk
medications occur all too frequently and result in permanent harm to patients,"
said Karl Ross, President of ABMI. "ValiMed MVS provides an answer that is
saving lives today. We are pleased to partner with CDEX in bringing this
lifesaving product line, as well as the ID2 Meth Scanner, to the Government
market on our GSA Contract Schedule. There has been a great deal of interest for
both products and we now have a contract vehicle to make it happen."
"We are very pleased to be on the GSA Schedule and look forward to working more
closely with ABMI in Government markets," said Malcolm Philips, CDEX CEO.
"Interest in our two product lines continues to be strong. Being placed on the
GSA Schedule is happening at the right time with a thawing in the economic
markets. We see 2010 shaping up to be a very good year for CDEX sales."
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare
and security markets. The ValiMed(TM) MVS product line provides life-saving
validation of high-risk medications and returned narcotics. The ID2(TM) product
line detects trace amounts of illegal drugs, such as methamphetamine. CDEX
expects to advance its patented technologies to serve additional markets. To
meet its plans, CDEX must strengthen its financial position as stated
periodically in its SEC filings. For more information, contact Malcolm Philips
at mphilips@cdex-inc.com.
About ABMI
ABMI Corporation is a Service-Disabled Veteran-Owned Small Business and an SBA
certified HUB-Zone Corporation that has partnered with Fortune 500 Companies
such as Grainger, Agilent Technologies, and Goodyear to manage procurement
contract processes related to Public Policy Goal Attainment acquisitions. ABMI
has a proven record of providing the highest quality products, with proven
customer satisfaction, translating into a very strong reputation among Veteran
Administration Hospitals and Federal Agencies. For more information see
www.abmicorp.com.
Non-historical statements are forward-looking, as defined in federal securities
laws, and generally can be identified by words such as "expects," "plans,"
"may," "believes," "should," "intends," and similar words. These statements pose
risks that cannot be accurately predicted. Consequently, results may differ
materially from those expressed or implied. Such risks and uncertainties
include, without limitation, the effectiveness, profitability and marketability
of products, the protection of intellectual property and proprietary
information, and other risks detailed periodically in filings with the SEC.
There is no obligation to update any forward-looking statements.
Contact:
Malcolm Philips
News for 'CEXI' - (ValiMed(TM) Launched in the Middle East by Virtus Trading LLC Major Presentations and Seminars by CDEX and Virtus to Health Officials Mark the Launch of ValiMed in the Middle East)
TUCSON, AZ and ABU DHABI, UNITED ARAB EMIRATES, Nov 16, 2009 (MARKETWIRE via
COMTEX) -- CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) and Virtus Trading LLC
announce that Malcolm Philips, CEO of CDEX, and Anil Pinto, Executive Director
at Virtus, recently met with senior officials of health ministries, hospital
administrators and pharmacists and conducted seminars on Medication Safety to
the medical communities in Abu Dhabi, Dubai, Kuwait and Saudi Arabia as part of
the regional launch of the ValiMed(TM) Medication Validation System. Worldwide
studies continue to show that human errors in the compounding of high-risk
medications occur frequently and result in permanent harm to patients throughout
the world. The seminars focused on actions to minimize mistakes and the ValiMed
technological safety net that provides protection for patients, pharmacists and
hospitals.
"The message presented in the seminars was very well received and we are
confident that the Middle East will be a strong market for ValiMed given current
momentum on raising patient care standards across the region," said Mr. Pinto.
"We at Virtus and Virtus Al-Essa look forward to a very long and successful
association with CDEX."
"It was a privilege to talk to the pharmacy teams in this region, some of the
best in the world, and it was reinforced to me that compounding errors and their
devastating aftermath know no geographical boundaries," said Mr. Philips. "We
are honored to partner with Virtus in bringing the ValiMed technology to
hospitals in this region. They share with CDEX and its growing number of ValiMed
clients a passion for patient safety."
CDEX Inc - Illegal activity of CDEX management described by CDEX Distributor John Comstock;
Let me see if I understand Mr. White's research that he sent out on Saturday 9/26/09.
Malcolm Philips and Don Strickland are old time buddies, along with Jim Griffin. They have been in involved in this same kind of scheme in the past as they are attempting to pull on the investors of CDEX.
This is my interpretation of why things have taken the turns they have since Malcolm planned his move to Cornelius NC. in September 2008 when he bought his new residence.
The plan was to completely destroy the validity of Dr. Poteet's and his team in their technology. Boast of the international connections, as they did with IPIX, fail to disclose factual problems about the technology to potential big money investors (Gemini) and others, like yourself, Jeff B., Jeff A, Pete M. Peter D. etc., but continue to go back to the various money troughs asking for more running capital while they work on the glitches. Myself and others getting involved with the actual use of the technology caused a very REAL danger to Philips, Shriver (s), Strickland and Griffin and the others that had pulled off this scheme as they did in 2004 with IPIX.
As I learned in September and October 2008 our findings and suggestions about the ID2 scanners were not being passed onto to the technical teams and Dr. Poteet for review per Malcolm Philips denying them access to problems. Malcolm needed to have control over the direction to cause the failure or at least have a plan to discredit the validity of the technology.
The problem that Malcolm Philips and his band of merry men DID NOT COUNT ON was that Dr. Poteet and his team actually developed a something that REALLY WORKED.
Events: Malcolm gets $1M+ from Gemini in October 1, 2008.
Stops paying Dr. Poteet and his team of scientists. BUT because Dr. Poteet and team know they have a great products, they continue to work believing Malcolm Philips will stand behind them.
In November and December Dr. Poteet and his team are developing and improving the technology to be 100% reliable. Malcolm stops any further contact with Meth Lab Cleanup Inc. in S.D., because they are getting too close to having a final product for home inspectors and remediation company's.
January they end working with Meth Lab CLean UP Inc. and Steve leaves the company.
During this time Dr. Poteet and Jim Ryles develop an all in one scanner for drugs and other signatures, plus discover some problems with Valimed. Malcolm CANNOT afford to let them add additional signatures that Europe asks for, because that would validate the valimed and he needed to have Europe get angry and pull out of using the Valimed, but still claim to have international usage, as they DID WITH IPIX in 2004.
Since Malcolm could not get Dr. Poteet and his team to simply quit because he stopped paying them in Oct 2008, he then needed to find other ways to get rid of them, AS THEY WERE AN ASSET and were determined to provide reliable products.
Thus Malcolm and Shriver Sr. just pushed them out the front doors by ####### them off time and time again.
Malcolm Philips then seized the moment in April 2009 when he instructed Tim Jr. to ensure enough FALSE POSITIVES in Washington news report to cast shadows upon the scanning technology.
Had already gotten rid of the Technical team by this time and was continuing with his plan to discredit Dr. Poteet and his teams products.
By posting, and even to this day, they still post news reports that appear favorable, but have never posted the NEWS REPORT from their own State of Arizona.
It appears that Malcolm and his band of merry men are now at the same point they were in 2006. NO MORE MONEY TO FLEECE.
BUT THE BIGGEST problem that Malcolm, Strickland and Shriver(s) have is that THE SCIENCE ACTUALLY WORKS. By having the company survive will cause the books to be reviewed by new people and discover the potential criminal enterprise that was contrived by Malcolm and the others as they did with IPIX.
THEY JUST NEVER REALLY expected this kind of technology to actually work!!! Look at the number of times Malcolm over the years stalled in getting the Valimed out, let alone the ID2.
Malcolm saw the writing on the wall in September and October 2008 that they were too close to being sucessful, so in order for no one to discover his illegal schemes he began a program to cause CDEX to fail or to be dissolved so he could walk away with his loot before the Gemini note came due. I am sure Malcolm, Shriver(s), Strickland and others are disappointed that they have not been able to get the doors closed yet.
Too many people discovered that this technology is valid and actually works and is a gold mine, if allowed to continue. That Malcolm can not allow and is on a mission to cause CDEX to close its doors as soon as possible so he gets another free ride on the backs of others.
News for 'CEXI' - (Geisinger Medical Center Proactively Enhances Its Medication Safety Program by Selecting the ValiMed(TM) Medication Safety System)
TUCSON, AZ, Sep 09, 2009 (MARKETWIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
(www.cdexinc.com) -- Worldwide studies show that high-risk medication
compounding errors in pharmacies continue to cause significant harm to patients
and economic loss to hospitals. Geisinger Medical Center joins a growing list of
world-class hospitals that are proactively addressing this issue by selecting
the ValiMed(TM) Medication Safety System to assure the "Right Drug at the Right
Dose" every time. ValiMed is used to validate accurate compounding of high-risk
medications and to reduce the diversion of return narcotics in healthcare
facilities.
"After reading the University of Michigan Health System study that documented
ValiMed's identification of five major medical mistakes over an 18 month period
at one hospital, I knew that we needed to bring that technology in-house," said
John Jones, Geisinger Vice President, System Therapeutics. "We purchased two
ValiMed units to provide additional assurance of accuracy of our compounding
practices."
"We are honored that Geisinger Medical Center selected ValiMed as part of its
Medication Safety Program and look forward to working with John and his staff in
integrating ValiMed into their daily practices," said Greg Firmbach, Senior Vice
President of CDEX.